Allan Doctor

Professor of Pediatrics & Director, Center for Blood Oxygen Transport and Hemostasis; CSO & Founding Partner, KaloCyte

Role: Chief Scientific Officer and Founding Partner at Kalocyte, Inc
Location: Baltimore, MD, US
LinkedIn followers: 500 followers

ScienceView LinkedIn profile

Experience

Chief Scientific Officer and Founding Partner
Kalocyte, Inc
Jan 2016 — Present · Baltimore, MD, US
Biotech start up formed to develop a novel bio-synthetic hybrid artificial red blood cell as first-in-class \'nano-cyte\'.

Education

University of Virginia
Bachelor of Science (B.S.), Neurobiology and Neurosciences
1980 — 1984
University of Virginia
MD, Medicine
1985 — 1989
University of Virginia
Doctor of Medicine (M.D.)
1985 — 1989

Skills

Healthcare
Epidemiology
Medicine
Icu
Medical Research
Cancer
Public Health
Board Certified
Clinical Trials
Critical Care
Hospitals
Healthcare Management
Emergency Medicine
Infectious Diseases
Clinical Research
Pediatrics
Medical Education
Molecular Biology
Surgery
Quality Improvement
Biotechnology
Intensive Care
Patient Safety

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@kalocyte.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Kalocyte, Inc

Biotechnology Research · 23 employees · Founded 2016 · Baltimore, Maryland, United States

KaloCyte, Inc, a preclinical biotech that has developed an artificial RBC substitute for use as a lifeline when blood is not available. We are located at the University of Maryland, Baltimore (UMB) as an Affiliate of the UM BioPark, and were selected as a BLUE KNIGHT™ Company. KaloCyte offices and labs are sited within the UM School of Medicine’s Center for Blood Oxygen Transport and Hemostasis (CBOTH) directed by Allan Doctor, MD (KaloCyte Co-Founder and CSO). KaloCyte was founded in 2016 by a distinguished team of Washington University in St. Louis researchers in physiology, bioengineering, and trauma care, with support from the BioGenerator Fundamentals program. KaloCyte has demonstrated preclinical safety and efficacy for ErythroMer, a shelf-stable, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by $17M in federal awards and $5M investor funding. ErythroMer is a first-in-class, bio-inspired nanoparticle-encapsulated human hemoglobin, which mimics the vital oxygen-carrying functionality of RBCs and can be freeze-dried for long-term storage. Erythromer’s synthetic outer membrane, small size and surface area allow for physiologically realistic gas exchange. The synthetic polymer shell is “immune-silent”, inert and carries no blood antigens, eliminating the need to type and cross-match as with stored blood. ErythroMer can be freeze-dried or “lyophilized”, for a much longer shelf life than stored blood. It is covered by issued U.S. patents that specify composition of matter, method of preparation, and use as an oxygen carrier.

kalocyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Chief Scientific Officer and Founding Partner

Education

University of Virginia

University of Virginia

University of Virginia

Skills

Find verified contacts for anyone on LinkedIn